Vaccine technology: looking to the future

References

• Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489–95
   PubMed Web of Science ®Google Scholar
• Hilleman M R. Vaccine perspectives from the vantage of hepatitis B. Vaccine Res 1992; 1: 1–15
   Google Scholar
• Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris M T, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989; 246: 497–9
   PubMed Web of Science ®Google Scholar
• Almond J W. The attenuation of poliovirus neurovirulence. Annu Rev Microbiol 1987; 41: 153–80
   PubMed Web of Science ®Google Scholar
• Sutter G, Wyatt L S, Foley P L, Bennink J R, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12: 1032–40
   PubMed Web of Science ®Google Scholar
• Bishop R F, Barnes G L, Cipiranti E, Lund J S. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309: 72
   PubMed Web of Science ®Google Scholar
• Maassab H F, DeBorde D C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985; 3: 355–71
   PubMed Web of Science ®Google Scholar
• Bloom B R, Fine P EM. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: Pathogenesis, Protection, and Control, B R Bloom. ASM Press, Washington, DC 1994; 531–58
   Google Scholar
• Levine M M. Typhoid fever vaccines. Vaccines, 2nd, S A Plotkin, E A Mortimer. Saunders, Philadelphia, PA 1994; 597–634
   Google Scholar
• Tartaglia J, Perkus M E, Taylor J. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188: 217–32
   PubMed Web of Science ®Google Scholar
• Daniel M D, Kirchhoff F, Czajak S C, Sehgal P K, Desrosiers R C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938–40
   PubMed Web of Science ®Google Scholar
• Chanock R M, Murphy B R, Collins P L, Coelingh K V, Olmsted R A, Snyder M H, et al. Live viral vaccines for respiratory and enteric tract diseases. Vaccine 1988; 6: 129–33
   PubMed Web of Science ®Google Scholar
• Kilbourne E D. Inactivated influenza vaccines. Vaccines, 2nd edn., S A Plotkin, E A Mortimer. Saunders, Philadelphia, PA 1994; 565–81
   Google Scholar
• Mortimer E A. Pertussis vaccine. Vaccines., 2nd edn., S A Plotkin, E A Mortirner. Saunders, Phildelphia, PA 1994; 91–136
   Google Scholar
• Jones F G, Moss J M. Studies on tetanus toxoid. I. The antitoxic titer of human subject following immunization with tetanus toxoid and tetanus alum precipitated toxoid. J Immunol 1936; 30: 115–25
   Google Scholar
• Milch D R. Immune response to hepatitis B virus: infection, animal models, vaccination. Viral Hepatis. Springer Verlag, ViennaAustria 1997; Vol 3: 63–103
   Google Scholar
• Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602–14
   PubMed Web of Science ®Google Scholar
• Iizuka N, Kohara M, Hagino-Yamagishi K, Abe S, Komatsu T, Tago K, et al. Construction of less neurovirulent polio-viruses by introducing deletions into the 5′-noncoding sequence of the genome. J Virol 1989; 63: 5354–63
   PubMed Web of Science ®Google Scholar
• Kaper J B, Tacket C O, Levine M M. New and improved vaccines against cholera. New Generation Vaccines., 2nd edn., M M Levine, G C Woodrow, J B Kaper, G S Cobon. Marcel Dekker, New York 1997; 447–58
   Google Scholar
• Levine M M, Tacket C O, Galen J E, Barry E M, Chatfield S N, Dougan G, . Progress in development of new attenuated strains of Salmonella typhi as live oral vaccines. New Generation Vaccines., 2nd edn, M M Levine, G C Woodrow, J B Kaper, G S Cobon, et al. Marcel Dekker, New York 1997; 437–46
   Google Scholar
• Valenzuela P, Medina A, Rutter W J, Ammener G, Hall B D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347–50
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Tron F, Vinas R, Mevelec M N, Diaz I, Couroucé A M, . Hepatitis B vaccine containing the S and preS-2 antigens produced in Chinese hamster ovary cells. Viral Hepatitis and Liver Disease, A J Zuckerman, et al. Alan R Liss, New York 1988; 263–90
   Google Scholar
• Paoletti E, Lipinskas B R, Samsonoff C, Mercer S, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1984; 81: 193–7
   PubMed Web of Science ®Google Scholar
• Jacobs W R, Jr., Snapper S B, Lugosi L, Bloom B R. Development of BCG as a recombinant vaccine vehicle. Curr Top Microbiol Immunol 1990; 155: 153–60
   PubMed Web of Science ®Google Scholar
• Donnelly J J, Ulmer J B, Liu M A. Immunization with DNA. J Immunol Methods 1994; 176: 145–52
   PubMed Web of Science ®Google Scholar
• Chai S K, Clavijo P, Tam J P, Zavala F. Immunogenic properties of multiple antigen peptide systems containing defined T-epitope and B-epitope. J Immunol 1992; 147: 2385–90
   Google Scholar
• Grzych J M, Capron M, Lambert P H, Dissous C, Torres S, Capron A. An anti-idiotype vaccine against experimental schistosomiasis. Nature 1985; 316: 74–6
   PubMed Web of Science ®Google Scholar
• Siber G R. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385–7
   PubMed Web of Science ®Google Scholar
• Arntzen C J, Mason H S, Shi J, Haq T A, Estes M K, Clements J D. Transgenic plants as vaccine production systems. Vaccines 1994: Modern Approaches to New Vaccines Including Prevention of AIDS, F Brown, R M Chanock, H S Ginsberg, R A Lerner. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1994; 239–244
   Google Scholar
• Mason H S, Lam D MK, Arntzen C J. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992; 89: 11745–9
   PubMed Web of Science ®Google Scholar
• May G D, Afza R, Mason H S, Weicko A, Novak F J, Arntzen C J. Generation of transgenic banana (Musa acuminata) plants via Agrobacterium-mediated transformation. Biotechnology 1995; 13: 486–92
   Web of Science ®Google Scholar
• McGarvey P B, Hammond J, Dienelt M M, Hooper D C, Fu Z F, Dietzschold B, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995; 13: 1484–7
   PubMed Web of Science ®Google Scholar
• Mason H S, Arntzen C J. Transgenic plants as vaccine production systems. Trends Biotechnol 1995; 13: 388–92
   PubMed Web of Science ®Google Scholar
• Gupta R K, Siber G R. Adjuvants for human vaccines -current status, problems and future prospects. Vaccine 1995; 14: 1263–76
   Web of Science ®Google Scholar
• Moms W, Steinhoff M C, Russell P K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12: 5–11
   PubMed Web of Science ®Google Scholar
• Heath A W, Playfair J HL. Cytokines as immunological adjuvants. Vaccine 1992; 10: 427–34
   PubMed Web of Science ®Google Scholar
• Valensi J PM, Carlson J R, Van Nest G A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994; 143: 4029–39
   Google Scholar
• Stürchler D, Berger R, Etlinger H, Fernex M, Matile H, Pink R, et al. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 1989; 7: 457–61
   PubMed Web of Science ®Google Scholar
• Andre F E, Peetermans J. Effect of simultaneous administration of live measles vaccine on the “take rate” of live mumps vaccine. Dev Biol Stand 1986; 65: 101–7
   PubMedGoogle Scholar
• Arbeter A M, Baker L, Starr S E, Levine B L, Books E, Plotkin S A. Combination measles, mumps, rubella and varicella vaccine. Pediatrics 1986; 78(4 Pt 2)742–7
   PubMed Web of Science ®Google Scholar
• Dagan R, Botujansky C, Watemberg N, Arbelli Y, Belmaker I, Ethevenaux C, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994; 13: 356–61
   PubMed Web of Science ®Google Scholar
• André F E. Development of combined vaccines: manufacturers' viewpoint. Biologicals 1994; 22: 317–21
   PubMed Web of Science ®Google Scholar
• Rogers B L, Morgenstern J P, Griffith I J, Yu X B, Counsell C M, Brauer A W, et al. Complete sequence of the allergen Amb alpha II. Recombinant expression and reactivity with T cells from ragweed allergic patients. J Immunol 1991; 147: 2547–52
   PubMed Web of Science ®Google Scholar
• Ada G L, Griffin P D. Vaccines for Fertility Regulation: The Assessment of Their Safety and Efficacy. Cambridge University Press, CambridgeUK 1991
   Google Scholar
• Hellström I, Hellstrom K E. Tumor immunology: an overview. Ann N Y Acad Sci 1993; 690: 24–33
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson D A, Arita I, Jazek Z, Ladnyi I O. Smallpox and Its Eradication. World Health Organization, Geneva 1988
   Google Scholar
• The Americas conquer polio. EPI Newsletter 1994; 4: 1–3
   Google Scholar